Post marketing surveillance to evaluate Soolantra cream 1% for the treatment of inflammatory lesions of rosacea in adult patients

Study identification

• EU PAS number:
  EUPAS22329
• Study ID:
  22330
• Official title and acronym:
  Post marketing surveillance to evaluate Soolantra cream 1% for the treatment of inflammatory lesions of rosacea in adult patients
• DARWIN EU® study:
  No
• Study countries:
  Korea, Republic of
• Study status:
  Planned

Research institutions and networks

Institutions

Galderma Korea

Study timelines

Date when funding contract was signed

Planned: 31/08/2017

Actual: 31/08/2017

Study start date

Planned: 15/12/2017

Data analysis start date

Planned: 31/07/2018

Date of interim report, if expected

Planned: 22/10/2018

Date of final study report

Planned: 22/10/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Galderma Korea Ltd.

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable